Therapeutic options in minimizing left ventricular hypertrophy

Area of Science:

• Cardiology
• Hypertension Research
• Pharmacology

Background:

• Left ventricular hypertrophy (LVH) is a significant risk factor for mortality in hypertensive patients.
• LVH is linked to increased risks of cardiovascular events including heart failure, stroke, and sudden death.
• The renin-angiotensin system is implicated in the development of LVH.

Purpose of the Study:

• To review the role of antihypertensive agents in LVH regression.
• To explore the potential of angiotensin receptor blockers (ARBs) in managing LVH.
• To highlight the specific mechanisms of ARBs in reducing left ventricular mass.

Main Methods:

• Review of existing literature on antihypertensive therapies and LVH.
• Analysis of studies investigating the effects of various drug classes on left ventricular mass.
• Examination of preclinical and clinical data on ARBs for LVH regression.

Main Results:

• All major antihypertensive classes can induce LVH regression, but efficacy varies.
• Angiotensin-converting enzyme inhibitors (ACE inhibitors) demonstrate significant blood pressure-independent effects on LVH.
• Angiotensin receptor blockers (ARBs) show promise, with studies indicating significant LVH regression, potentially via AT(2) receptor activation.

Conclusions:

• ARBs represent a promising therapeutic option for LVH regression in hypertensive patients.
• Targeting the renin-angiotensin system, particularly with ARBs, may offer superior benefits for reducing left ventricular mass.
• Further research is warranted to fully elucidate the long-term benefits and optimal use of ARBs in managing LVH.